Management Credibility Analysis

Unavailable
Verified Management Score Unavailable
Management credibility requires sourced guidance and earnings history.

Upcoming Catalysts

Verified event feed
Verified Catalysts Unavailable
No sourced upcoming event feed is configured for this stock yet.

Company profile

No description available

Chief executive
Not disclosed
Headquarters
675 WEST KENDALL STREET, CAMBRIDGE, MA
Founded
Not disclosed

📈 Company Timeline

Major business events
Positive
Negative
Neutral
30 Jul 2026

Alnylam Pharmaceuticals, Inc. filed Form 10-Q

Alnylam Pharmaceuticals, Inc. submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.

30 Jul 2026

Alnylam Pharmaceuticals, Inc. reported Operating or financial results

Alnylam Pharmaceuticals, Inc. filed an 8-K covering operating or financial results, supporting financial statements or exhibits.

28 May 2026

Alnylam Pharmaceuticals, Inc. reported A director or senior management change or compensation event

Alnylam Pharmaceuticals, Inc. filed an 8-K covering a director or senior management change or compensation event, shareholder voting results.

14 May 2026

Large-holder ownership filing

A holder reported or amended a beneficial ownership position of more than 5% in Alnylam Pharmaceuticals, Inc..

14 May 2026

Large-holder ownership filing

A holder reported or amended a beneficial ownership position of more than 5% in Alnylam Pharmaceuticals, Inc..

Capital Structure & Financial Position

Financial strength and liquidity analysis
Cash and equivalents (USD)$1.71B
Total assets (USD)$5.56B
Total liabilities (USD)$4.20B
Shareholders' equity (USD)$1.35B
Long-term debt (USD)$677.72M

Source: SEC EDGAR company facts (opens in a new tab) Balance sheet dated

Peer Comparison - Health Care

Company Price Market Cap
LLY - Eli Lilly and Company $1,276.13
Yahoo Finance 		$1.20T
JNJ - Johnson & Johnson $256.74
Yahoo Finance 		$618.71B
ABBV - AbbVie Inc. $284.80
Yahoo Finance 		$503.28B
UNH - UnitedHealth Group Incorporated $418.43
Yahoo Finance 		$375.58B
MRK - Merck & Co., Inc. $148.55
Yahoo Finance 		$366.50B

📋 Corporate Actions

Recent and upcoming corporate events
Verified Corporate Actions Unavailable
Dividend, buyback, split, and spin-off feeds are not ingested for this stock yet.

Financials

Financial statements and key metrics analysis
QuarterRevenue (USD)Operating incomeNet incomeDiluted EPS (USD)Filed
Q2 2026$1.29B$231.44M$164.49M$1.2110-Q · 30 Jul 2026
Q4 2025$1.10B$131.72M$111.54MUnavailable10-K · 12 Feb 2026
Q3 2025$1.25B$367.98M$251.08M$1.8410-Q · 30 Oct 2025
Q2 2025$773.69M−$16.20M−$72.23M−$0.5510-Q · 31 Jul 2025
Q1 2025$594.19M$18.08M−$18.25M−$0.1410-Q · 1 May 2025
Q4 2024$593.17M−$105.16M−$83.76MUnavailable10-K · 13 Feb 2025

Source: SEC EDGAR company facts (opens in a new tab)

Analyst Consensus

Buy
Target: $364.76
56.4% upside potential
📈
Strong Buy
Unavailable
👍
Buy
19
⏸️
Hold
4
📉
Sell
0
23 analysts covering this stock

Source: Nasdaq analyst research (opens in a new tab) Retrieved Targets range 253.00–489.00 Ratings are third-party opinions, not advice.

💰 Upcoming Dividends

Next dividend payments
Verified Dividend Data Unavailable
Dividend calendar data is not ingested for this stock yet.

Guidance Evolution

Verified Guidance History Unavailable
Verified company guidance history is not ingested for this stock yet.

💼 Director Transactions

Recent insider activity
2
Oct 2026
SUPRAN BRYAN
EVP, CLO and Secretary
Open-market sale
$226.88 per share
1,758 shares
SEC Form 4
19
Sep 2026
Greenstreet Yvonne
Director, Chief Executive Officer
Grant or award
Unavailable per share
107 shares
SEC Form 4
1
Jun 2026
PYOTT DAVID E I
Director
Option exercise
Unavailable per share
3,830 shares
SEC Form 4
1
Jun 2026
PYOTT DAVID E I
Director
Open-market sale
$299.18 per share
3,830 shares
SEC Form 4
20
May 2026
Sigal Charles Elliott
Director
Grant or award
Unavailable per share
671 shares
SEC Form 4
20
May 2026
SCHULMAN AMY W
Director
Grant or award
Unavailable per share
838 shares
SEC Form 4
20
May 2026
Reitan Colleen F
Director
Grant or award
Unavailable per share
671 shares
SEC Form 4
20
May 2026
PYOTT DAVID E I
Director
Grant or award
Unavailable per share
671 shares
SEC Form 4

Top Shareholders

Fmr Llc
15,023,962 shares
3.051% change
6/30/2026
Vanguard Group Inc
13,553,932 shares
-0.085% change
12/31/2025
Capital World Investors
11,144,846 shares
3.171% change
6/30/2026
Blackrock, Inc.
10,907,675 shares
4.431% change
6/30/2026
Capital Research Global Investors
9,750,699 shares
2.951% change
6/30/2026
Vanguard Portfolio Management Llc
6,538,390 shares
0.726% change
6/30/2026
Vanguard Capital Management Llc
6,029,478 shares
1.392% change
6/30/2026
T. Rowe Price Investment Management, Inc.
5,642,173 shares
8.643% change
6/30/2026
Invesco Ltd.
3,754,318 shares
-7.872% change
6/30/2026
State Street Corp
3,555,689 shares
7.012% change
6/30/2026

Source: Nasdaq institutional holdings (opens in a new tab) Observed · 1 day ago